approv us fda better-than-
approv expect taim name trogarzo
approv march nearli one month april review
deadlin think approv came expect drug
previous receiv breakthrough therapi orphan drug design
well prioriti review statu fda approv
administr intraven bi-weekli could use combin
antiretrovir medic uniqu first
treatment new class antiretrovir call inhibitor first
biolog treatment first treatment hiv drug requir
daili dose first treatment new mechan action approv
year first fda approv protein drug product taiwan
wholesal price higher expect taim partner set
wholesal price per patient per annum net
sale price around discount wholesal price way
ahead expect manag prior guidanc
think higher price limit impact penetr given
major patient cover medic insur
readi commerci launch within six week total address
market us estim patient per annum
european approv expect taim partner meet
regul ema european medicin agenc mid-april target
submit packag approv believ suggest tmb-
could receiv approv ema start ship
rais tp revis ep
better price higher gm off-set higher opex introduc ep
retain outperform lift tp
base revis dcf model impli average ep
valuat metric
chang previou ep
number share mn
price month
price rel chart measur perform
taiwan se weight close
spot exchang
rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
taim focus develop drug treatment
price rate outperform target price analyst jerri su
good sold
profit tax
free cash flow firm
net chang cash
blue sky scenario valuat base
price-to-earnings blue sky scenario assum higher
penetr us european patient
grey sky scenario valuat base
price-to-earnings grey sky scneario assum lower
penetr us europ
price rel chart measur perform taiwan se
weight close
spot exchang rate
figur address market us
figur prolifer us eu
average patient eu
average patient us
figur taim revenu take
gener
pre-clin start phase aug
phase complet
pre-clin start phase
therapeut prevent
therapeut prevent
easier rout administr
compar iv infus
broader spectrum potent efficaci
improv pk profil compar
formul sc/im inject
potenti weekly/monthli dose
prong attack hiv entri add
breadth potenc
charl martineau pm univers toronto rais tp
set
sever record hiv
approv us fda
taim name trogarzo receiv us fda food drug
administr bla biolog licens applic approv march drug
expect launch us six week approv came expect
annual wholesal price announc taim
sale partner
per patient market expect think higher
price much impact penetr major patient cover
medic insur believ approv us fda acceler discuss
ema late approv
revis ep better price higher
gm off-set higher opex introduc ep reiter
outperform lift tp base revis dcf
model impli averag ep taim remain top pick taiwan
target mdr patient
approv patient multi-drug resist mdr whose hiv
infect success treat current avail therapi fda
approv administr intraven bi-weekli could use
combin antiretrovir medic accord taim
drug-drug interact cross-resist art antiretrovir therapi
previous receiv breakthrough therapi orphan drug design
well prioriti review statu fda moreov also sever uniqu
featur list
first treatment new class antiretrovir call inhibitor
first biolog treatment
first treatment hiv drug requir daili dose
first treatment new mechan action approv year
first fda approv protein drug product taiwan
first humanis monoclon antibodi approv work
bind receptor host cell block hiv viru infect cell
phase clinic trial indic patient enrol studi p-
valu met primari endpoint least viral load reduct
follow seven-day treatment period averag viral load reduct
week treatment initi viral load patient achiev
undetect viral load believ superior result could support adopt
mdr patient hiv transmitt suppress
undetect level accord studi us cdc center diseas control
us eu address market patient
accord taim file fda believ us total mn
hiv infect popul patient treatment studi also
show total number hiv patient mdr us half
popul requir new treatment everi year believ european patient popul
mdr similar size us henc address market us europ
patient per annum
figur us address market patient per annum
market us
estim
europ
given treatment regim hiv experienc signific improv past
decad global hiv infect patient remain upward trend believ
suggest taim address market could sustain level us
europ next sever year taim extend partnership
theratechnolog us european market march manag said
next meet ema offici mid-april discuss
target submit applic approv juli believ suggest
could receiv approv ema start contribut revenu
could also expand address market develop asia believ
take time complet applic approv process
peopl live hiv
figur global hiv patient region
north
north
europ
wholesal price
per annum ahead
price higher-than-expect
taim enter market contract theratechnolog march
year exclus distribut us canada upon fda approv
amend agreement theratechnolog march market
distribut european countri regular basi net-revenu
split taim partner us european
market could increas european market annual sale
mn execut contract
mn worth tsx share commerci launch
mn worth tsx share upon fda approv
figur taim market contract theratechnolog
mn worth tsx common share within day contract
direct out-of-pocket develop cost mandat ema
mn payabl one year launch
mn payabl one year sale reach mn
taim get net sale annual sale mn
taim get net sale annual sale mn
mn worth tsx share upon commerci launch
mn payabl quarterli instal
taim get net sale
us upon approv bi-weekli im
mn upon approv monthli sc/im
mn upon achiev mn sale quarter
mn upon achiev annual sale mn
mn upon achiev annual sale mn
mn upon achiev annual sale mn
mn upon achiev annual sale mn
mn upon achiev annual sale mn
mn upon achiev annual sale mn
theratechnolog conduct file studi engag major insur
compani past year us well establish better
stronger sale forc promot annual wholesal price announc today
per patient rebat price discount wholesal price
market expect compani guidanc believ
longer act period bi-weekli vs daili hiv drug less side
effect smaller patient popul potenti reduct addit medic
expens patient hospitalis mdr support price
higher level think higher price much impact penetr
mdr patient major patient cover medic insur
figur theratechnolog sale team expans launch
commerci launch within six week
follow fda approv taim target complet label packag
within month ship product partner alreadi inventori
warehous us theratechnolog also said confer call
work sever distributor includ rxcrossroad option walgreen
alliancerx accredo curascript distribut
theratechnolog said host product launch meet end march
target finalis set payer polici insur compani parti
within six week believ take four-to-six month see pick-up mdr
patient adopt expect momentum acceler afterward taim believ
drug reach peak sale third fourth year launch
figur averag market penetr hiv antiretrovir therapi
grow pipelin hiv treatment
taim extens grow pipelin hiv treatment follow approv
intraven inject iv infus conduct small clinic trial
patient
manag believ im inject could receiv fda approv within one
year could help prolifer mdr patient im inject easier rout
administr compar iv infus
develop remain track start phase clinic trial
next gener co-develop taim
dr david ho team aaron diamond aid research centr adarc accord
preclin data could offer broader coverag hiv infect
potent efficaci improv pharmacokinet versu tmb-
bi-monthli
taim solid
pipelin hiv
receiv us fda approv begin phase studi decemb
expect conclud proteas inhibitor hiv drug taim
licens ambrilia biopharma offer long-act antiretrovir
treatment hiv infect use nanotechnolog formul could lead least
fold reduct particl size molecul nano-scal rang nanonis
nanosuspens would increas dissolut rate aqueou solut
enhanc bioavailabl human bodi decreas drug consumpt medic
cost compar daili oral pill preliminari studi rat dog monkey shown
nanosuspens high potenti monthli treatment hiv patient
tmb-bispecif third gener recombin monoclon antibodi taim
licens adarc tmb-bispecif uniqu structur biolog
activ target two differ antigen one target human receptor like tmb-
target hiv envelop protein like hiv infect
manag expect tmb-bispecif start phase studi
gener
pre-clin start phase aug
phase complet
pre-clin start phase
therapeut prevent
therapeut prevent
easier rout administr
compar iv infus
broader spectrum potent efficaci
improv pk profil compar
formul sc/im inject
potenti weekly/monthli dose
prong attack hiv entri add
breadth potenc
could cheaper
outsourc
in-hous product enhanc cost structur
taim work wuxipharma produc wuxipharma
pass us fda site inspect use scale dispos bioreactor
mass product estim cost manufactur wuxipharma
patient per annum think translat gm
taim base announc wholesal price per annum
taim board director also decid construct product site chupei
taiwan august rais total capital-expenditure initi mn one line
scale bioreactor bn greater in-hous capac
bioreactor manag said breakdown mn
construct facil mn equip mn process
valid target complet construct clean room august
start equip move conduct three batch process valid
twelv month stabil data appli fda site
inspect
estim product cost in-hous capac cheaper vs outsourc
impli gm produc in-hous capac could reach
estim gradual ramp intern capac expect tmb-
shift back in-hous product
rais tp reiter outperform
revis ep better price higher
gm off-set higher opex introduc ep reiter
outperform rate taim lift tp base
revis dcf model impli averag ep taim remain top pick
taiwan pharmaceut sector
figur prolifer us eu
average patient eu
average patient us
figur taim revenu take
figur taim share price under-perform
theratechnolog sinc partnership
full note investor meet
taim host investor meet post approv pm taiwan time
march compani repres ceo dr jame chang cfo chen
vice-president dr meng-hsin chen full note meet
review deadlin delay januari april
fda howev impress achiev given size
enter new stage launch product start
fda advis taim expand beyond research compani
go manufactur start build plant chupei
 interact fda close notic grown
care help us grow bigger
amaz drug price reason excel perform
hiv drug year exist improv lot
new class drug approv
better other due longer last less side effect
per annual whole sale price higher expect
price base consid breakthrough orphan drug
comparison hiv drug
theratechnolog consult insur compani
around insur compani said price reason
bottl inventori
label box take week
theratechnolog expect week start sell
ema approv relev cost support theratechnolog
bla us transfer
fda packag appli ema approv
get approv multipl countri one time con
need time approv
dutch itali repres countri review
expect get approv within one year possibl
theratechnolog target submit applic juli
eu us approv differ
studi minor
us fda requir pdh children clinic trial need
provid safeti data children use indic
orphan drug need provid safeti data
children henc focus adult
europ ema requir pdh clinic trial stage
uncertainti negoti
ema submit pdh data afterward
us price limit eu limit
eu us term theratechnolog
us transfer price net sale matter sell-through drug
wholesal price price discount distribut
pharmaci insur compani
net sale price wholesal price minu promot minu
net sale could wholesal price initi could
promot could higher first two year launch
eu transfer price net sale price annual sale mn
exce mn
contract mn valu share receiv
approv date anoth mn valu share
launch date set share price
payment signatur year ago mn cash mn equival
valu common share common share deliv taim upon
approv bla price set negoti date
up-front launch mileston mn equal valu common share share
price base averag bla approv date
 plan dispos share near-term given
strateg partner view there valu hold onto stock
small clinic trial requir patient henc trial within one
address market peak sale theratechnolog said mdr popul
us around peopl look new drug
view
us cdc estim hiv posit popul mn peopl mdr
around round patient
theratechnolog estim mdr patient need look new
drug add potenti clients/target patient
 target least penetr
sale year launch mean sale
could reach peak us
relev cost pay genetech mn cabil mn
one-off expens amortis
mileston payment recognis intang asset amortis
year
theratechnolog stock gather- prepaid revenu amount mn
two amortis expens impact much
think margin go forward consid royalti
royalti payment follow slide scale increas sale increas
think averag royalti stay less level life-cycle
drug
higher price benefit
 gm close
transfer price royalti payment
staff move new site april equip instal juli
product insourc overal product cost
significantli
gross margin still forecast despit whole sale price higher expect
price set high product contain lot uncertainti
product could differ huge year later effici
produc protein could go etc
that price higher remain conserv margin
net sale price forecast net profit margin
side effect drug mention packag insert
 one look potenti side effect also refer
sever hiv drug life threaten like peer
possibl list packag insert
indic mainli mdr patient focus group larger popul
appli orphan drug design fda ask us approach
patient possibl need less patient that
includ target patient take medicin time need drug
chang includ packag insert
us physician decid appli patient
one mention packag insert
sale forc follow instruct packag insert
progress satisfi pace
 work templ univers still on-going
phase cohort studi complet onto cohort studi
target complet
consid new drug new nanonis technolog fda
requir cohort studi done separ independ henc lengthi
ship warehous recognis revenu
theratechnolog send order quarterli basi begin given
pipelin drug pipelin gap
way prevent gap pipelin
intramuscular inject launch one year
enter phase juli aug
enhanc version
alreadi phase
tmb-bispecif enter phase
licens aaron diamond aid research centr adarc
adarc valu project lot work year
fund gate foundat result good
phase spend mostli adarc
adarc fund cost
spent one product cost gmp batch
proceed aid treatment aaron diamond kept hold
prevent spend develop start go
prevent spend money
project enter phase ii
project along launch provid on-going
inflow compani prepar launch year
go beyond drug develop compani start
manufactur chupei
chupei capac batch per year serv demand popul
enhanc version
wont extend research focu oper effici
enhanc version good need focu
work go front line treatment perhap line
higher rd clinic trial given start
make money problem
 deal mid-term
like us think stuff
intramuscular inject dose differ overal size
label extens dose instruct
inject time need significantli reduc
intraven inject requir intramuscular inject
could need
judg current patient behavior patient goe clinic
intraven inject go inject servic centr use
intramuscular inject help prefer go
doctors/clin inject
fda also approv hiv front-lin drug what take
four-in-on front-lin hiv drug approv februari
impact tam
drug compani rush front line market less come last
hiv drug work effect seen decreas death rate
longer life time infect rate rise us eu
accord prolifer continu
grow third fourth year launch stabilis afterward
 set high price price first three year stabl
see slight growth inflat afterward dont think declin
compani mention price
